On Oct. 9, 2026, the Pennsylvania Governor’s Office announced the Commonwealth has secured an over $800 million investment from GSK to expand its operations in Montgomery County. The expansion will create more than 300 new jobs over the next five years, retain approximately 4,500 existing full-time jobs across the Commonwealth,and continue growing Pennsylvania’s robust life sciences industry.

GSK is expanding its facilities in Upper Merion Township, with construction planned to begin in 2027. The expansion will establish a biopharmaceutical innovation and manufacturing hub, integrating commercial production, research and development, and advanced digital capabilities in a single site. This announcement marks GSK’s second major expansion in Pennsylvania since the Governor took office, previously investing $800 million in Lancaster County — investing a total of nearly $1.7 billion in the Commonwealth.

The expansion project will include the demolition of existing buildings and construction of new and enhanced facilities including a commercial-scale biologics manufacturing facility capable of supporting both clinical and commercial supply, a co-located research and development pilot plant to accelerate tech transfer and process development, and a centralized quality control lab and manufacturing science & technology (MSAT) hub.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. The company’s US headquarters is in Philadelphia, with global headquarters located in London, England.